Non-Hodgkin Lymphoma Market to Register Incremental Growth | AbbVie and Genmab, Roche, AstraZeneca, 4SC AG, Innate Pharma,Teva Pharma, Eli Lilly, and other companies are expected to change the Market scenario by 2032, forecasts DelveInsight.

{Delhi, India} To strategically aid Non-Hodgkin Lymphoma companies developing drugs for Non-Hodgkin Lymphoma, DelveInsight launched a report titled as “Non-Hodgkin's Lymphoma Market Insight, Epidemiology And Market Forecast - 2032”. This comprehensive report delves into epidemiology based market analysis, providing a roadmap for success in the dynamic landscape of Non-Hodgkin Lymphoma market.

Get a free sample of “Non-Hodgkin's Lymphoma Market Insight and Forecast Report” : 

Key Highlights from Non-Hodgkin Lymphoma market Report:

• The Non-Hodgkin Lymphoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• Roche's POLIVY and ADC Therapeutics' ZYLNONTA represent two approved ADCs for DLBCL. ZYLNONTA and POLIVY combined with bendamustine and rituximab (BR) are potential preferred treatment options for individuals experiencing primary resistance.
• Key Non-Hodgkin Lymphoma Companies: AbbVie and Genmab, Roche, AstraZeneca, 4SC AG, Kartos Therapeutics, Innate Pharma,Baxter International Inc., Bayer AG, Bristol Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Eli Lilly, F. Hoffmann La-Roche Ltd, GlaxoSmithKline PLC., and others
• Key Non-Hodgkin Lymphoma Therapies: Epcoritamab, POLIVY, AZD4573, Resminostat, Navtemadlin, Lacutamab (IPH4102), and others
• The Non-Hodgkin Lymphoma epidemiology based on gender analyzed that males have higher incident cases of DLBCL as compared to females, and this trend is expected to remain the same during the study period.
• The Non-Hodgkin Lymphoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non-Hodgkin Lymphoma pipeline products will significantly revolutionize the Non-Hodgkin Lymphoma market dynamics. 

Non-Hodgkin Lymphoma Country based Treatment Overview: 

The Non-Hodgkin's Lymphoma treatment section entails information regarding both traditional and contemporary medical treatments accessible in the market for managing this condition. Additionally, it offers treatment algorithms and guidelines specific to Non-Hodgkin's Lymphoma in the United States, Europe, and Japan.

Non-Hodgkin Lymphoma (NHL) is a cancer type that commonly originates in the lymph nodes and lymphatic tissue present in organs like the stomach, intestines, or skin. Occasionally, NHL affects the bone marrow and blood. It isn't a singular disease but rather encompasses a varied range of blood cancers emerging from lymphocytes, which are a type of white blood cells integral to the immune system. 

To Know in detail about the Non-Hodgkin Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Non-Hodgkin Lymphoma Market Forecast

Non-Hodgkin Lymphoma Epidemiology Insights: 

The epidemiology segment on Non-Hodgkin's Lymphoma offers insights into the historical and present patient population, as well as predicted trends across seven major countries. It aids in understanding the reasons behind current and projected trends through an exploration of various studies and perspectives from key opinion leaders.

 “Per the American Cancer Society, Non-Hodgkin lymphoma (NHL) ranks among the prevalent cancers in the United States, making up approximately 4% of all cancer cases. Projections indicate an estimated 80,550 individuals (44,880 males and 35,670 females), encompassing both adults and children, will receive NHL diagnoses in 2023.”

"The collective new cases of DLBCL across the 7MM were estimated at approximately 75,000 in 2022, with an anticipated rise anticipated throughout the study period spanning from 2019 to 2032. Within the 7MM, the United States recorded the highest incidence of DLBCL, trailed by the EU4, the UK, and Japan." 

Non-Hodgkin Lymphoma Epidemiology Segmentation:

The Non-Hodgkin Lymphoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Non-Hodgkin Lymphoma
• Prevalent Cases of Non-Hodgkin Lymphoma by severity
• Gender-specific Prevalence of Non-Hodgkin Lymphoma
• Diagnosed Cases of Episodic and Chronic Non-Hodgkin Lymphoma

Download the report to understand which factors are driving Non-Hodgkin Lymphoma epidemiology trends @ Non-Hodgkin Lymphoma Epidemiology Forecast

Non-Hodgkin Lymphoma Therapies and Key Companies

• Epcoritamab: AbbVie and Genmab
• POLIVY: Roche
• AZD4573: AstraZeneca
• Resminostat: 4SC AG
• Navtemadlin: Kartos Therapeutics
• Lacutamab (IPH4102): Innate Pharma 

Emerging Non-Hodgkin Lymphoma drugs Uptake:

The drug chapter section within the Non-Hodgkin's Lymphoma report comprises an in-depth analysis of both the existing market drugs for Non-Hodgkin's Lymphoma and late-stage pipeline drugs (Phase III and Phase II).

“In May 2023, The FDA in the United States has granted approval for the investigational new drug (IND) application from SIRPant Immunotherapeutics. This allows the commencement of a phase I clinical trial, the first of its kind, aimed at treating relapsed refractory non-Hodgkin lymphoma.”

“In May 2023, The FDA in the United States authorized AbbVie's EPKINLY (epcoritamab-bysp), a T-cell engaging bispecific antibody, for treating adult patients diagnosed with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).”

The FDA in the United States has approved several drugs for Non-Hodgkin lymphoma treatment, including ISTODAX (romidepsin), VALCHLOR (mechlorethamine), UVADEX (methoxsalen), TARGRETIN (bexarotene), ADCETRIS (brentuximab vedotin), POTELIGO (mogamulizumab), and ZOLINZA (vorinostat).

Discover more about therapies set to grab major Non-Hodgkin Lymphoma market share @ Non-Hodgkin Lymphoma Treatment Landscape

Non-Hodgkin Lymphoma Market Forecast:

The market outlook section of the report on Non-Hodgkin's Lymphoma aids in establishing a comprehensive understanding of past, present, and anticipated market trends. It accomplishes this by examining the influence of existing Non-Hodgkin's Lymphoma therapies on the market, identifying unmet needs, evaluating drivers and barriers, and assessing the demand for improved technology.

"The anticipated introduction of potential therapies like Epcoritamab (AbbVie and Genmab), Glofitamab (Roche), AZD4573 (AstraZeneca), Lacutamab (Innate Pharma), Resminostat (4SC AG), SGX301 (HyBryte), and others is poised to expand the market size in the future. This growth is expected to be supported by a rise in the population affected by NHL."

The market drivers include - Premium-price agents with superior efficacy such as CAR-T cell therapies and kinase inhibitors are expected to dominate the NHL market, the recent launch of therapies such as HIYASTA for ATLL and PTCL, DARVIAS, and REMITORO for R/R PTCL in Japan provides more treatment options for patients with PTCL 

Scope of the Non-Hodgkin Lymphoma Market Report:

• Geography Coverage: 7MM
• Study Period: 2019-2032
• Key Non-Hodgkin Lymphoma Companies: AbbVie and Genmab, Roche, AstraZeneca, 4SC AG, Kartos Therapeutics, Innate Pharma,Baxter International Inc., Bayer AG, Bristol Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Eli Lilly, F. Hoffmann La-Roche Ltd, GlaxoSmithKline PLC., and others

To know more about Non-Hodgkin Lymphoma companies working in the treatment market, visit @ Non-Hodgkin Lymphoma Clinical Trials and Therapeutic Assessment

Related Reports: 

Non-Hodgkin Lymphoma Pipeline  

"Non-Hodgkin Lymphoma Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Non-Hodgkin Lymphoma market. A detailed picture of the Non-Hodgkin Lymphoma pipeline landscape is provided, which includes the disease overview and Non-Hodgkin Lymphoma treatment guidelines. 

Non-Hodgkin Lymphoma Epidemiology 

DelveInsight's 'Non-Hodgkin Lymphoma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Non-Hodgkin Lymphoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Gaurav Bora

Email: info@delveinsight.com

Contact No.: +91-9650213330

City: 304 S. Jones Blvd #2432, Las Vegas

State:  Nevada (89107)

Country: United States

Website: https://www.delveinsight.com/consulting